Erika Hamilton: Data that pCR translates to outcome in TNBC

Erika Hamilton shared a post on X:

“PEARLY: Adriamycin Cyclophosphamide (AC) to Taxane versus AC to T carboplatin among Triple-negative breast cancer (TNBC) Lymph Node (LN)+ or 2cm.

7.2% increase in Event-free survival (EFS) with the addition of carboplatin.

Overall Survival (OS) is already very close to significant with 3.7% different, p 0.058.

Very compelling data that Pathologic Complete Response (pCR) translates to outcome in TNBC.”

Source: Erika Hamilton/X

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.

Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee.

She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.